MENU
AMGN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

AMGN stock forecast, quote, news & analysis

Amgen is a leader in biotechnology-based human therapeutics... Show more

Industry: #Biotechnology
A.I.Advisor
published price charts
AMGN
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for AMGN with price predictions
Oct 06, 2026

AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 01, 2026

The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMGN's RSI Oscillator exited the oversold zone, 17 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 31 of 48 cases over the following month. The odds of a continued upward trend are 65%.

Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 191 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.

AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMGN as a result. In 36 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.

AMGN moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.

The Aroon Indicator for AMGN entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.342) is normal, around the industry mean (19.199). P/E Ratio (25.971) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.025) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).

The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

A.I.Advisor
published Dividends

AMGN paid dividends on September 11, 2026

Amgen AMGN Stock Dividends
А dividend of $2.52 per share was paid with a record date of September 11, 2026, and an ex-dividend date of August 21, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 200.13B. The market cap for tickers in the group ranges from 4.8K to 1.06T. LLY holds the highest valuation in this group at 1.06T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 8%. NSRX experienced the highest price growth at 8%, while MIRA experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -11%. For the same stocks of the Industry, the average monthly volume growth was 15% and the average quarterly volume growth was -8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 27
P/E Growth Rating: 53
Price Growth Rating: 56
SMR Rating: 59
Profit Risk Rating: 64
Seasonality Score: 2 (-100 ... +100)
AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 01, 2026